| Gray's anatomy: the anatomical basis of clinical practice S Standring, H Ellis, J Healy, D Johnson, A Williams, P Collins, C Wigley American journal of neuroradiology 26 (10), 2703, 2005 | 9720 | 2005 |
| Cyclophosphamide versus placebo in scleroderma lung disease DP Tashkin, R Elashoff, PJ Clements, J Goldin, MD Roth, DE Furst, ... New England Journal of Medicine 354 (25), 2655-2666, 2006 | 1899 | 2006 |
| Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease: a randomized, controlled trial DB Badesch, VF Tapson, MD McGoon, BH Brundage, LJ Rubin, ... Annals of internal medicine 132 (6), 425-434, 2000 | 1448 | 2000 |
| Update of EULAR recommendations for the treatment of systemic sclerosis O Kowal-Bielecka, J Fransen, J Avouac, M Becker, A Kulak, Y Allanore, ... Annals of the rheumatic diseases 76 (8), 1327-1339, 2017 | 1109 | 2017 |
| Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. P Clements, P Lachenbruch, J Siebold, B White, S Weiner, R Martin, ... The Journal of rheumatology 22 (7), 1281-1285, 1995 | 1076 | 1995 |
| Joint injury in young adults and risk for subsequent knee and hip osteoarthritis AC Gelber, MC Hochberg, LA Mead, NY Wang, FM Wigley, MJ Klag Annals of internal medicine 133 (5), 321-328, 2000 | 980 | 2000 |
| Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial DP Tashkin, MD Roth, PJ Clements, DE Furst, D Khanna, EC Kleerup, ... The lancet Respiratory medicine 4 (9), 708-719, 2016 | 963 | 2016 |
| Raynaud's phenomenon FM Wigley New England Journal of Medicine 347 (13), 1001-1008, 2002 | 954* | 2002 |
| EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR) O Kowal-Bielecka, R Landewé, J Avouac, S Chwiesko, I Miniati, L Czirjak, ... Annals of the rheumatic diseases 68 (5), 620-628, 2009 | 888 | 2009 |
| Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial M Matucci-Cerinic, CP Denton, DE Furst, MD Mayes, VM Hsu, ... Annals of the rheumatic diseases 70 (1), 32-38, 2011 | 582 | 2011 |
| Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease DP Tashkin, R Elashoff, PJ Clements, MD Roth, DE Furst, RM Silver, ... American journal of respiratory and critical care medicine 176 (10), 1026-1034, 2007 | 577 | 2007 |
| A disease‐specific activity index for Wegener's granulomatosis: modification of the Birmingham Vasculitis Activity Score JH Stone, GS Hoffman, PA Merkel, YI Min, ML Uhlfelder, DB Hellmann, ... Arthritis & Rheumatism 44 (4), 912-920, 2001 | 545 | 2001 |
| Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis B White, WC Moore, FM Wigley, HQ Xiao, RA Wise Annals of internal medicine 132 (12), 947-954, 2000 | 512 | 2000 |
| Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study FM Wigley, RA Wise, JR Seibold, DA McCloskey, G Kujala, TA Medsger, ... Annals of internal medicine 120 (3), 199-206, 1994 | 507 | 1994 |
| Genome-wide association study of systemic sclerosis identifies CD247 as a new susceptibility locus TRDJ Radstake, O Gorlova, B Rueda, JE Martin, BZ Alizadeh, ... Nature genetics 42 (5), 426-429, 2010 | 452 | 2010 |
| Evidence that systemic sclerosis is a vascular disease M Matucci‐Cerinic, B Kahaleh, FM Wigley Arthritis & Rheumatism 65 (8), 1953-1962, 2013 | 450 | 2013 |
| Association of the autoimmune disease scleroderma with an immunologic response to cancer CG Joseph, E Darrah, AA Shah, AD Skora, LA Casciola-Rosen, ... Science 343 (6167), 152-157, 2014 | 443 | 2014 |
| High‐dose versus low‐dose D‐penicillamine in early diffuse systemic sclerosis: analysis of a two‐year, double‐blind, randomized, controlled clinical trial PJ Clements, DE Furst, WK Wong, M Mayes, B White, F Wigley, ... Arthritis & Rheumatism: Official Journal of the American College of …, 1999 | 438 | 1999 |
| Clinical differences between idiopathic and scleroderma‐related pulmonary hypertension MR Fisher, SC Mathai, HC Champion, RE Girgis, T Housten‐Harris, ... Arthritis & Rheumatism 54 (9), 3043-3050, 2006 | 423 | 2006 |
| Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon PA Merkel, K Herlyn, RW Martin, JJ Anderson, MD Mayes, P Bell, JH Korn, ... Arthritis & Rheumatism 46 (9), 2410-2420, 2002 | 410 | 2002 |
